| 4.7 -0.75 (-13.76%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.41 | 1-year : | 18.44 |
| Resists | First : | 11.48 | Second : | 15.78 |
| Pivot price | 5.69 |
|||
| Supports | First : | 4.53 | Second : | 3.76 |
| MAs | MA(5) : | 5.06 |
MA(20) : | 6.38 |
| MA(100) : | 5.76 |
MA(250) : | 19.62 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 17.6  |
| RSI | RSI(14): 36.9 |
|||
| 52-week | High : | 80.09 | Low : | 2.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SPRC ] has closed above bottom band by 19.7%. Bollinger Bands are 27.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.03 - 5.07 | 5.07 - 5.09 |
| Low: | 4.55 - 4.58 | 4.58 - 4.61 |
| Close: | 4.65 - 4.7 | 4.7 - 4.75 |
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Thu, 09 Jul 2026
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Thu, 02 Jul 2026
SPRC Stock Price, Quote & Chart - ChartMill
Thu, 04 Jun 2026
SciSparc (NASDAQ: SPRC) unit NeuroThera acquires 54% of CliniQuantum in CAD$9.46M share deal - Stock Titan
Wed, 03 Jun 2026
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd. - TheNewswire
Wed, 03 Jun 2026
Director Itschak Shrem Sells Shares of SciSparc Ltd (SPRC) - GuruFocus
Thu, 28 May 2026
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | 98.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 142.32 |
| Profit Margin | 0 % |
| Operating Margin | -849 % |
| Return on Assets (ttm) | -60.7 % |
| Return on Equity (ttm) | -178.4 % |
| Qtrly Rev. Growth | -34.5 % |
| Gross Profit (p.s.) | 1.1 |
| Sales Per Share | 1.49 |
| EBITDA (p.s.) | -14.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 0.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.03 |
| Price to Sales | 3.14 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|